80303-91-9

Basic information

• Product Name: 1,4-bis[(3-nitrophenyl)sulfonyl]piperazine
• Synonyms: piperazine, 1,4-bis[(3-nitrophenyl)sulfonyl]-
• CAS NO: 80303-91-9
• Molecular Formula: C₁₆H₁₆N₄O₈S₂
• Molecular Weight: 456.4502
• Mol File: 80303-91-9.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 670.7°C at 760 mmHg
• Flash Point: 359.4°C
• Density: 1.591g/cm³
• Vapor Pressure: 7.54E-18mmHg at 25°C
• Refractive Index: 1.656
• CAS DataBase Reference: 1,4-bis[(3-nitrophenyl)sulfonyl]piperazine(CAS DataBase Reference)
• NIST Chemistry Reference: 1,4-bis[(3-nitrophenyl)sulfonyl]piperazine(80303-91-9)
• EPA Substance Registry System: 1,4-bis[(3-nitrophenyl)sulfonyl]piperazine(80303-91-9)

Safety Data

• Hazardous Substances Data: 80303-91-9(Hazardous Substances Data)

Usage

Chemical Class

Piperazine derivatives

Physical Appearance

White to slightly yellow crystalline powder

Primary Use

Reagent in the synthesis of various bioactive molecules and pharmaceutical compounds

Reactivity

Highly reactive compound

Nitro Groups

Potential nitroso transfer reagent

Application

Development of new drugs and research tool in pharmaceutical and biotechnology industries

Safety Precautions

Toxic if inhaled, absorbed through the skin, or ingested

Potential Hazards

May cause irritation to the respiratory system, skin, and eyes

Upstream product

• 110-85-0 piperazine 
• 121-51-7 3-nitrobenzenesulphonyl chloride 

Relevant articles and documents

Synthesis, biological evaluation, and qpld studies of piperazine derivatives as potential dpp-iv inhibitors

Background: Diabetes mellitus is a serious global health issue, currently affecting 425 million people and is set to affect over 690 million people by 2045. It is a chronic disease characterized by hyperglycemia due to relative or absolute insulin hormone deficiency. Dipeptidyl peptidaseIV (DPP-IV) inhibitors are hypoglycemic agents augmenting the action of the incretin hormones that stimulate insulin secretion from the pancreatic beta cells. Objective: In this study, synthesis and biological evaluation of seven piperazine derivatives 3a-g was carried out. Methods: The synthesized molecules were characterized using proton-nuclear magnetic resonance, carbon-nuclear magnetic resonance, infrared spectroscopy and mass spectrometry. Results: In vitro biological evaluation study showed comparable DPP-IV inhibitory activity for the targeted compounds ranging from 19%-30% at 100 μM concentration. Furthermore, the in vivo hypoglycemic activity of 3d was evaluated using streptozotocin-induced diabetic mice. It was found that compound 3d significantly decreased the blood glucose level when the diabetic group treated with 3d was compared to the control diabetic group. Quantum–Polarized Ligand Docking (QPLD) studies demonstrate that 3a-g fit the binding site of DPP-IV enzyme and form H-bonding with the backbones of R125, E205, E206, K554, W629, Y631, Y662, R669, and Y752. Conclusion: Piperazine derivatives were successfully found to be new scaffolds as potential DPP-IV inhibitors.